Stock Track | Novavax Plunges 8.71% in Pre-Market as 2026 Revenue Guidance Falls Short of Analyst Expectations

Stock Track

Feb 26

Novavax's stock experienced a significant pre-market plunge of 8.71% on Thursday, following the release of its fourth quarter and full year 2025 financial results.

The biotech company reported better-than-expected Q4 results with earnings of $0.11 per share and revenue of $147.1 million, beating analyst estimates. However, investors reacted negatively to the company's 2026 adjusted revenue guidance of $230 million to $270 million, which falls significantly short of the analyst consensus estimate of $377 million.

While Novavax raised its 2026 outlook from previous forecasts and highlighted strength in vaccine supply and licensing deals, the guidance disappointment overshadowed the positive quarterly results. The company continues to face challenges from restrictive U.S. recommendations for COVID-19 shots and sagging demand, though milestone payments from partnerships with Sanofi and Pfizer are expected to provide some offset.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1150796506"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150796506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150796506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150796506","market":"sg","top_or_hot":-1,"title":"Stock Track | Novavax Plunges 8.71% in Pre-Market as 2026 Revenue Guidance Falls Short of Analyst Expectations","media":"Stock Track","content":"<p>Novavax's stock experienced a significant pre-market plunge of 8.71% on Thursday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The biotech company reported better-than-expected Q4 results with earnings of $0.11 per share and revenue of $147.1 million, beating analyst estimates. However, investors reacted negatively to the company's 2026 adjusted revenue guidance of $230 million to $270 million, which falls significantly short of the analyst consensus estimate of $377 million.</p><p>While Novavax raised its 2026 outlook from previous forecasts and highlighted strength in vaccine supply and licensing deals, the guidance disappointment overshadowed the positive quarterly results. The company continues to face challenges from restrictive U.S. recommendations for COVID-19 shots and sagging demand, though milestone payments from partnerships with Sanofi and Pfizer are expected to provide some offset.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Plunges 8.71% in Pre-Market as 2026 Revenue Guidance Falls Short of Analyst Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Plunges 8.71% in Pre-Market as 2026 Revenue Guidance Falls Short of Analyst Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax's stock experienced a significant pre-market plunge of 8.71% on Thursday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The biotech company reported better-than-expected Q4 results with earnings of $0.11 per share and revenue of $147.1 million, beating analyst estimates. However, investors reacted negatively to the company's 2026 adjusted revenue guidance of $230 million to $270 million, which falls significantly short of the analyst consensus estimate of $377 million.</p><p>While Novavax raised its 2026 outlook from previous forecasts and highlighted strength in vaccine supply and licensing deals, the guidance disappointment overshadowed the positive quarterly results. The company continues to face challenges from restrictive U.S. recommendations for COVID-19 shots and sagging demand, though milestone payments from partnerships with Sanofi and Pfizer are expected to provide some offset.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1150796506","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150796506","pubTimestamp":1772111329,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novavax's stock experienced a significant pre-market plunge of 8.71% on Thursday, following the release of its fourth quarter and full year 2025 financial results.The biotech company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"个股追踪|2026年营收指引不及分析师预期Novavax盘前暴跌8.71%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax's stock experienced a significant pre-market plunge of 8.71% on Thursday, following the release of its fourth quarter and full year 2025 financial results.The biotech company reported better-than-expected Q4 results with earnings of $0.11 per share and revenue of $147.1 million, beating analyst estimates. However, investors reacted negatively to the company's 2026 adjusted revenue guidance of $230 million to $270 million, which falls significantly short of the analyst consensus estimate of $377 million.While Novavax raised its 2026 outlook from previous forecasts and highlighted strength in vaccine supply and licensing deals, the guidance disappointment overshadowed the positive quarterly results. The company continues to face challenges from restrictive U.S. recommendations for COVID-19 shots and sagging demand, though milestone payments from partnerships with Sanofi and Pfizer are expected to provide some offset.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}